Abstract
Background It is not clear whether previous thyroid diseases influence the course and outcomes of COVID-19. The study aims to compare clinical characteristics and outcomes of COVID-19 patients with and without hypothyroidism.
Methods The study is a part of a multicentric cohort of patients with confirmed COVID-19 diagnosis, including data collected from 37 hospitals. Matching for age, sex, number of comorbidities and hospital was performed to select the patients without hypothyroidism for the paired analysis.
Results From 7,762 COVID-19 patients, 526 had previously diagnosed hypothyroidism (50%) and 526 were selected as matched controls. The median age was 70 (interquartile range 59.0-80.0) years-old and 68.3% were females. The prevalence of underlying comorbidities were similar between groups, except for coronary and chronic kidney diseases, that had a higher prevalence in the hypothyroidism group (9.7% vs. 5.7%, p=0.015 and 9.9% vs. 4.8%, p=0.001, respectively). At hospital presentation, patients with hypothyroidism had a lower frequency of respiratory rate > 24 breaths per minute (36.1% vs 42.0%; p=0.050) and need of mechanical ventilation (4.0% vs 7.4%; p=0.016). D-dimer levels were slightly lower in hypothyroid patients (2.3 times higher than the reference value vs 2.9 times higher; p=0.037). In-hospital management was similar between groups, but hospital length-of-stay (8 vs 9 days; p=0.029) and mechanical ventilation requirement (25.4% vs. 33.1%; p=0.006) were lower for patients with hypothyroidism. There was a trend of lower in-hospital mortality in patients with hypothyroidism (22.1% vs. 27.0%; p=0.062).
Conclusion In this large Brazilian COVID-19 Registry, patients with hypothyroidism had a lower requirement of mechanical ventilation, and showed a trend of lower in-hospital mortality. Therefore, hypothyroidism does not seem to be associated with a worse prognosis, and should not be considered among the comorbidities that indicate a risk factor for COVID-19 severity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by Minas Gerais State Agency for Research and Development (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais - FAPEMIG) [grant number APQ-00208-20], National Institute of Science and Technology for Health Technology Assessment (Instituto de Avaliacao de Tecnologias em Saude - IATS)/ National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq) [grant number 465518/2014-1 and 147122/2021-0]. DNP was funded by a research scholarship from IATS/CNPq [grant number 147122/2021-0].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been conducted by a protocol approved by the National Commission for Research Ethics (CAAE 30350820.5.1001.0008). Individual informed consent was waived due to the pandemic and to the fact that all data collected was unidentified, gathered through medical records.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(Pereira DN - dani_nunesp{at}hotmail.com,)
(Silveira LFG- leticiafgs{at}ufmg.br.)
(Guimarães MMM - milenamg2{at}gmail.com)
(Polanczyk CA- carisi.anne{at}gmail.com)
(Nunes AGS- alinegsn89{at}yahoo.com.br)
(Costa ASM- andresmc{at}gmail.com)
(Farace BL- barbarafarace{at}gmail.com)
(Cimini CCR- christiane.cimini{at}gmail.com)
(Carvalho CAC- carvalho.cintiaa{at}gmail.com)
(Ponce D- daniela.ponce{at}unesp.br)
(Roesch EW- eroesch{at}hcpa.edu.br)
(Manenti ERF- eulermanenti{at}gmail.com)
(Lucas FB- fbl_lucas{at}yahoo.com.br)
(Rodrigues FA- fe.athayde{at}gmail.com)
(Anschau F- afernando{at}ghc.com.br)
(Aranha FG- fgaranha{at}icloud.com)
(Bartolazzi B- fredlazzi{at}hotmail.com)
(Vietta GG- ggvietta{at}gmail.com)
(Nascimento GF- guilhermefagundesn{at}hotmail.com)
(Duani H- hduani{at}yahoo.com.br)
(Vianna HR- hrvianna{at}hotmail.com)
(Guimarães HC - hcerqueirag{at}gmail.com,)
(Costa JHSM- jamillesalles{at}yahoo.com.br)
(Batista JAL- joannalyra{at}gmail.com)
(Alvarenga JC- joice-alvarenga{at}hotmail.com)
(Chatkin JM- jmchatkin{at}pucrs.br)
(Morais JDP- juliadrumond{at}hotmail.com)
(Machado-Rugolo J- jr.machado{at}unesp.br)
(Ruschel KB- karenbruschel{at}gmail.com)
(Pinheiro LS- lilian.pinheiro98{at}hotmail.com)
(Menezes LS- luannasmonteiro{at}gmail.com)
(Couto LSF- lucianasiuves{at}gmail.com)
(Kopittke L- kluciane{at}ghc.com.br)
(Castro LC- pharmlucamsc{at}gmail.com)
(Nasi LA- lnasi{at}terra.com.br)
(Cabral MA- madersonalvares{at}hotmail.com)
(Floriani MA- maiara.floriani{at}hmv.org.br)
(Souza MD- mairadiassouza{at}gmail.com)
(Carneiro M- marceloc{at}unisc.br)
(Bicalho MAC- macbicalho{at}gmail.com)
(Godoy MF- mfdegodoy{at}gmail.com)
(Nogueira MCA- mathnogueira42{at}gmail.com)
(Júnior MHG- miltonhenriques{at}yahoo.com.br)
(Oliveira NR- neimyramos{at}gmail.com)
(Sampaio NCS- natsamster{at}gmail.com)
(Assaf PL- pedro.ledic{at}hmdcc.com.br)
(Finger RG- renanfinger{at}yahoo.com.br)
(Campos RX- xaviercampos.roberta{at}gmail.com)
(Menezes RM- rochelemenezes{at}unisc.br)
(Francisco SC- saionaracf{at}gmail.com)
(Alvarenga SP- samuelpenchel{at}gmail.com)
(Guimarães SMM- smangeon{at}gmail.com)
(Araújo SF- silviaferreiragastro{at}gmail.com)
(Oliveira TF- talitafischeroliveira{at}gmail.com)
(Diniz THO- thuliodinizmed{at}gmail.com)
(Ramires YC- yuri.ramires{at}gmail.com)
(Cenci EPA- assistencial6_hu{at}centrodepesquisaclinica.com.br)
(Oliveira TC- thainarastaehler{at}hotmail.com)
(Schwarzbold AV- alexvspoa{at}gmail.com)
(Ziegelmann PK- patriciakz99{at}gmail.com)
(Pozza R- robertapozza{at}tacchini.com.br)
(Pires MC – magda{at}est.ufmg.br,)
(Marcolino MS - milenamarc{at}ufmg.br,)
E-mail: karenbruschel{at}gmail.com. 14MD. Rede Mater Dei de Saúde, Belo Horizonte, Brasil.
Data Availability
Data is available upon reasonable request.
LIST OF ABBREVIATIONS
- COVID-19
- Coronavirus disease 19
- NTIS
- Non-thyroidal illness syndrome
- T3
- Triiodothyronine
- T4
- Thyroxine
- TSH
- Thyroid-stimulating hormone
- ICU
- Intensive Care Unit
- REDCap
- Research Data Capture
- COPD
- Chronic obstructive pulmonary disease
- SF ratio
- Peripheral oxygen saturation/fraction of inspired oxygen ratio
- GCS
- Glasgow coma score
- HR
- Heart rate
- RR
- Respiratory rate
- Sat O2
- Peripheral capillary oxygen saturation
- aPTT
- Activated partial thromboplastin time
- AST
- Aspartate transaminase
- ALT
- Alanine aminotransferase
- BNP
- B-type natriuretic peptide
- CPK
- Creatine phosphokinase
- NT-proBNP
- N-terminal pro-brain natriuretic peptide
- INR
- International normalized ratio
- VTE
- Venous thromboembolism
- ACE 2
- Angiotensin-converting enzyme 2
